Corvus Pharmaceuticals, Inc
863 Mitten Road, Suite 102
Burlingame
CA
94010
United States
73 articles about Corvus Pharmaceuticals, Inc
-
For nearly 30 years, Richard Miller has been at the forefront of developing treatments for lymphomas, most notably the multi-billion dollar breakthroughs Rituxan and Imbruvica. In recognition of his decades of work, Miller was awarded with the 2020 Drug Hunter Award.
-
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
12/7/2019
Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy
-
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/8/2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody.
-
Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
11/7/2019
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it will present preclinical and early clinical data from its Phase 1/1b clinical trial of CPI-818 at the American Society of Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019.
-
Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
11/5/2019
Corvus Pharmaceuticals, Inc. announced that the company will present at the 28th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ.
-
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on Nov 8, Event will provide a review of updated CPI-006 data from Phase 1/1b study and data on adenosine gene signature in renal cell cancer with ciforadenant presented at SITC 2019
11/4/2019
BURLINGAME, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it is hosting an investor and analyst event on Friday, November 8, 2019 from 6:00 – 7:30 pm ET, during the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. The e
-
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial ResultsConference Call Today at 4:30 p.m. ET / 1:30 p.m. PT
10/29/2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported financial results for the third quarter ended September 30, 2019.
-
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
10/17/2019
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the Company will host a conference call and webcast on Tuesday, October 29, 2019 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2019 financial results.
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer
1/28/2019
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the appointment of Linda S. Grais, M.D., J.D., to the Company’s Board of Directors and Mehrdad Mobasher, M.D., M.P.H., as Vice President and Chief Medical Officer, effective immediately.
-
Corvus Pharmaceuticals Announces Publication of Preclinical Results Highlighting Antitumor Activity of CPI-444 in Multiple Tumor Models both as Monotherapy and in Combination Studies
10/3/2018
Corvus Pharmaceuticals, Inc. today announced the publication of results of preclinical studies of CPI-444 demonstrating that it induces dose dependent anti-tumor responses as a monotherapy and in combination with anti-PD-1, anti-PD-L1 and anti-CTLA-4 therapies.
-
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
8/2/2018
Corvus Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2018, and provided a business update.
-
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy
6/28/2018
Corvus Pharmaceuticals, Inc. announced publication of results of preclinical studies of CPI-444